Showing 2051-2060 of 2657 results for "".
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat RPhttps://modernod.com/news/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/2481784/ViGeneron announced that the European Medicines Agency (EMA) has approved the clinical trial application for VG901, a gene therapy to treat CNGA1-associated retinitis pigmentosa (RP). VG901 uses vgAAV, ViGeneron's proprietary adeno-associated virus (AAV) vector to deliver the CNGA1
- Haag-Streit to Present Ophthalmic Skills Training Center Concept at ESCRS 2023https://modernod.com/news/haag-streit-to-present-ophthalmic-skills-training-center-concept-at-escrs-2023/2481783/Haag-Streit announced it is showcasing the 'Ophthalmic Skills Training Center (OSTC)' at this year's Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). At the core of the Ophthalmic Skills Training Center is the combination of
- European Medicines Agency Accepts Iveric Bio’s Marketing Authorization Application for Avacincaptad Pegol for GAhttps://modernod.com/news/european-medicines-agency-accepts-iveric-bios-marketing-authorization-application-for-avacincaptad-pegol-for-geographic-atrophy/2481780/Two weeks after receiving FDA approval, the European Medicines Agency (EMA) has accepted for regulatory review Iveric Bio's marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) seco
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Euclid Vision Issues Statement on the Passing of Co-Founder George Gladyhttps://modernod.com/news/euclid-vision-issues-statement-on-the-passing-of-co-founder-george-glady/2481771/Euclid Vision issued a statement memorializing George Glady, one of the company's founders who has passed away. Mr. Glady was a pioneer in Ortho-K, which has been an innovation used by millions of patients around the world to slow the progression of myopia. The state
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene
- HelpMeSee and USAID Partner to Train New Cataract Specialists to Provide Surgical Care for India's Cataract Blindhttps://modernod.com/news/helpmesee-and-usaid-partner-to-train-new-cataract-specialists-to-provide-surgical-care-for-indias-cataract-blind/2481752/HelpMeSee announced a new partnership with the United States Agency for International Development (USAID) American Schools and Hospitals Abroad (ASHA) initiative to train 100 new cataract specialists to help restore sight to India's cataract blind. Through this agreement, ASHA has p
- Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United Stateshttps://modernod.com/news/versea-ophthalmics-will-distribute-celularitys-biovance-and-biovance-3l-ocular-products-in-the-united-states/2481750/Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00